GW Pharma’s Epidiolex descheduled from DEA (NASDAQ:GWPH)

The U.S. Drug Enforcement Agency (DEA) has advised GW Pharmaceuticals (NASDAQ:GWPH) it considers Epidiolex (cannabidiol) a regulated substance. The switch is effective immediately.

The transfer has been anticipated. Back in September 2018, the DEA took the intermediate phase of categorizing the merchandise as a Schedule 5 drug (contains cough suppressants that contain small amounts of codeine, Lyrica and Motofen) which possess lower abuse potential compared to Schedule 4 compounds (i.e., Xanax, Darvon, Ambien).

Shares up 4 percent premarket on light quantity.